Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277365 · ClinicalTrials.gov registry record · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
A NA study of Heart Diseases, sponsored by Scripps Translational Science Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 100,000
- Enrollment target
- 1
- Study location
NCT03277365 is a NA study of Heart Diseases that is actively recruiting participants, run by Scripps Translational Science Institute. The registered enrollment target is 100,000 participants, above the 4,356-participant average among 85 other Heart Diseases trials with a reported enrollment target (2196% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03277365, a NA study of Heart Diseases, is actively recruiting participants, sponsored by Scripps Translational Science Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 100,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Many conditions affecting health are caused by a combination of environment, behaviors, and genes. While individuals can alter some factors in their lives to reduce the chances of developing different diseases (e.g., not smoking cigarettes), the contribution from genetic risk encoded by DNA remains with people throughout their lives. Scientists are still trying to determine the entirety of genetic factors that influence disease, but for some conditions it has been shown that the factors identified thus far can begin to identify people at high to low genetic risk. Looking across the genome, scientists can calculate a cumulative genetic risk score - which can be used to rank genetic risk compared to other worldwide populations. The goal of this study is to determine how genetic risk influences health decisions and other things that can be controlled in life. The first genetic risk score is calculated for coronary heart disease (CAD). CAD ultimately leads to heart attacks, heart failure and sometimes sudden cardiac death and is the main reason heart disease remains as the number one cause of death worldwide. Other researchers have shown that this genetic risk score can be used to identify people with low, intermediate, and high risk for coronary heart disease. It has also been shown that the use of statins (cholesterol lowering drugs) provides greater benefit and protection against heart attack for people with high genetic risk for coronary artery disease. Leveraging the Apple ResearchKit and the ResearchKit linked 23andMe API, customers of 23andMe are able to provide researchers access to their genomic data. Participants will use the ResearchKit app to provide consent, view study information, answer surveys, and contact the study team. Participants will be asked to complete 3 surveys. One before viewing genetic risk scores, one immediately after viewing scores, and one 6 months after viewing scores.
Conditions Studied
Interventions
- OTHER Receive genetic risk information
Study Locations (1)
California
- Scripps Translational Science Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2017-09-26 |
| Est. Completion | 2030-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03277365
The ClinicalTrials.gov registry entry for NCT03277365 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,356-participant average among 85 other Heart Diseases trials with a reported enrollment target (2196% higher). The listed sponsor is Scripps Translational Science Institute, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Diseases appearing as the primary indexed condition, and to 1 intervention - of which Receive genetic risk information is the first listed.
NCT03277365 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03277365 about?
NCT03277365 is a clinical study titled "MyGeneRank: A Digital Platform for Next-Generation Genetic Studies". Many conditions affecting health are caused by a combination of environment, behaviors, and genes. While individuals can alter some factors in their lives to reduce the chances of developing different diseases (e.g., not smoking cigarettes), the contribution from genetic risk encoded by DNA remains ...
What is the current status of trial NCT03277365?
This trial is currently recruiting. It is a NA study. The enrollment target is 100,000 participants. The study started on 2017-09-26. Estimated completion is 2030-09.
What conditions does trial NCT03277365 study?
This clinical trial studies the following conditions: Heart Diseases.
What interventions are being tested in trial NCT03277365?
The interventions under investigation include: Receive genetic risk information (OTHER).
Who is sponsoring clinical trial NCT03277365?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03277365 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Angiography and Electrogram Guided Bachmann Bundle Pacing
RECRUITING · NA
-
Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health
RECRUITING · NA
-
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
RECRUITING · NA
-
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR
RECRUITING · NA
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
RECRUITING · NA
-
Use of Bedside Imaging and Community Health Workers for Early Screening and Referral of Pre-symptomatic Stage B Heart Failure in the Emergency Department
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.